Additional file 1: of Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

  • Jinyu Zhang (Creator)
  • Pablo Saenz Lopez Larrocha (Creator)
  • Bin Zhang (Creator)
  • Derek Wainwright (Creator)
  • Payal Dhar (Contributor)
  • Jennifer Donglan Wu (Creator)



Figure S1 Serum levels of sMICB in animal cohorts at pre-treatment baseline. Figure S2 sMIC expressing tumor cells elicited impaired response to anti-PD-L1 therapy. Figure S3 Cooperative therapy effect of anti-PD1 mAb and sMIC-targeting mAb B10G5. Figure S4 clearance of sMIC does not increase co-stimulatory molecules CD28 or NKG2D on CD4 T cells in tumor draining lymph node (dLN). Figure S5 Detection of sMIC (A and B) binds to NKG2D and B10G5 simultaneously. Figure S6 sMIC/B10G5 co-stimulation amplifies antigen-specific TCR-signaling through NKG2D. Figure S7 Therapy results in increase in NKG2D expression on NK cells. (PPTX 2068 kb)
Date made available2019

Cite this